Clinical and genetic features of Charcot-Marie-Tooth disease patients with IGHMBP2 mutations

• Published in: Neuromuscular disorders : NMD 2022-07, Vol.32 (7), p.564-571
• Main Authors: Lei, Liu, Zhiqiang, Lin, Xiaobo, Li, Zhengmao, Hu, Shunxiang, Huang, Huadong, Zhao, Beisha, Tang, Ruxu, Zhang
• Format: Article
• Language: English
• Subjects: AR-CMT2S; Genotype; IGHMBP2; Molecular structural model analysis; Phenotype
• ISSN: 0960-8966; 1873-2364
• DOI: 10.1016/j.nmd.2022.05.002

•We detect 8 typical AR-CMT2S families in our cohort of 178 Chinese CMT2 families.•Summarize the clinical and genetic features in all reported AR-CMT2S patients worldwide.•Classification of missense mutations might be helpful for establishing genotype-phenotype relationship. Autosomal recessive Charcot-Marie-Tooth disease Type 2S (AR-CMT2S) caused by IGHMBP2 mutation was first reported in 2014, and an increasing number of cases have been reported in the past eight years. We detected 15 distinct IGHMBP2 mutations among 8 typical AR-CMT2S families in our cohort of 178 Chinese CMT2 families using Sanger sequencing and next-generation sequencing (NGS), making IGHMBP2 mutations the most frequent cause of AR-CMT2 in our cohort. From 2014 to 2022, 34 AR-CMT2S families, including 45 patients and 47 different mutations, were reported. One third of identified mutations represented presumed loss-of-function variants (nonsense, frameshift and splicing), while two-thirds were missense changes which clustered in the helicase and ATPase domains. The age at onset ranged from 0.11 years to 20 years (mean±SD: 3.76±3.93 years) and the infantile (0–2 years) onset group accounted for the most patients (51.1%). The initial symptoms included muscle weakness (15, 33.3%), delayed milestones (9, 20%), feet deformity (8, 17.8%), gait disturbance (8, 17.8%), feet drop (7, 15.6%), frequent falls (3, 6.7%), hypotonia (2, 4.4%) and thenar atrophy (1, 2.2%). Molecular structural model analysis of 26 missense IGHMBP2 mutations using PyMOL software revealed that six mutations were close to the RNA-binding channel, eight mutations were in or close to the nucleotide-binding pocket. Based on available limited clinical information, it seems possible that missense changes located in or close to these motifs might be linked to a more severe clinical outcome. In conclusion, IGHMBP2 mutation screening should recommended for early-onset, moderately or severely affected, and sporadic or AR-CMT2 patients. A tiny minority of patients were relatively late onset and mild affected, which should be given more attention in genetic diagnosis and treatment. While our preliminary analysis suggests a potential link between the localization of missense mutations and clinical presentation, definition of genotype-phenotype relationships will require harmonized clinical information from a larger series of patients.